385 related articles for article (PubMed ID: 29896199)
1. Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8
Chen H; Chen Y; Liu H; Que Y; Zhang X; Zheng F
Front Immunol; 2018; 9():1179. PubMed ID: 29896199
[TBL] [Abstract][Full Text] [Related]
2. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.
Choi HS; Ha SY; Kim HM; Ahn SM; Kang MS; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kang ES
Oncotarget; 2016 Feb; 7(7):7940-51. PubMed ID: 26799288
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
4. Endogenous IL-33 exerts CD8
Xia Y; Ohno T; Nishii N; Bhingare A; Tachinami H; Kashima Y; Nagai S; Saito H; Nakae S; Azuma M
Biochem Biophys Res Commun; 2019 Oct; 518(2):331-336. PubMed ID: 31421832
[TBL] [Abstract][Full Text] [Related]
5. IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated, Th2 Biased and Suppress CD4 T Cell Proliferation through IL-10 and TGFβ Release.
Siede J; Fröhlich A; Datsi A; Hegazy AN; Varga DV; Holecska V; Saito H; Nakae S; Löhning M
PLoS One; 2016; 11(8):e0161507. PubMed ID: 27548066
[TBL] [Abstract][Full Text] [Related]
6. IL-33/ST2 as a potential target for tumor immunotherapy.
Jiang W; Lian J; Yue Y; Zhang Y
Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922
[TBL] [Abstract][Full Text] [Related]
7. CD45
Mao FY; Zhao YL; Lv YP; Teng YS; Kong H; Liu YG; Wu XL; Hao CJ; Chen W; Duan MB; Han B; Ma Q; Wang TT; Peng LS; Zhang JY; Cheng P; Su CY; Fu XL; Zou QM; Guo G; Guo XL; Zhuang Y
Cell Death Dis; 2018 Jul; 9(7):763. PubMed ID: 29988030
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-33 in Malignancies: Friends or Foes?
Shen JX; Liu J; Zhang GJ
Front Immunol; 2018; 9():3051. PubMed ID: 30619376
[TBL] [Abstract][Full Text] [Related]
9. IL-33 Alarmin and Its Active Proinflammatory Fragments Are Released in Small Intestine in Celiac Disease.
Perez F; Ruera CN; Miculan E; Carasi P; Dubois-Camacho K; Garbi L; Guzman L; Hermoso MA; Chirdo FG
Front Immunol; 2020; 11():581445. PubMed ID: 33133101
[TBL] [Abstract][Full Text] [Related]
10. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
11. Disruption of IL-33 Signaling Limits Early CD8+ T Cell Effector Function Leading to Exhaustion in Murine Hemophagocytic Lymphohistiocytosis.
Rood JE; Burn TN; Neal V; Chu N; Behrens EM
Front Immunol; 2018; 9():2642. PubMed ID: 30515155
[TBL] [Abstract][Full Text] [Related]
12. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.
Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R
Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137
[TBL] [Abstract][Full Text] [Related]
13. Increased Expression of sST2 in Early HIV Infected Patients Attenuated the IL-33 Induced T Cell Responses.
Wu X; Li Y; Song CB; Chen YL; Fu YJ; Jiang YJ; Ding HB; Shang H; Zhang ZN
Front Immunol; 2018; 9():2850. PubMed ID: 30564243
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-33, a Potential Cytokine Expressed in Tumor Microenvironment Involves in Antitumor Immunotherapy Through Facilitates CD8
Li X; Lv Q; Feng Y; Gu Y; Xia R; Ma J; He H; Zhu Y
J Interferon Cytokine Res; 2018 Nov; 38(11):491-499. PubMed ID: 30452317
[TBL] [Abstract][Full Text] [Related]
15. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.
Liu JF; Ma SR; Mao L; Bu LL; Yu GT; Li YC; Huang CF; Deng WW; Kulkarni AB; Zhang WF; Sun ZJ
Mol Oncol; 2017 Feb; 11(2):235-247. PubMed ID: 28102051
[TBL] [Abstract][Full Text] [Related]
16. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.
Matta BM; Reichenbach DK; Zhang X; Mathews L; Koehn BH; Dwyer GK; Lott JM; Uhl FM; Pfeifer D; Feser CJ; Smith MJ; Liu Q; Zeiser R; Blazar BR; Turnquist HR
Blood; 2016 Jul; 128(3):427-39. PubMed ID: 27222477
[TBL] [Abstract][Full Text] [Related]
17. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
18. Suppression of T cells by myeloid-derived suppressor cells in cancer.
Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.
Kim JR; Moon YJ; Kwon KS; Bae JS; Wagle S; Kim KM; Park HS; Lee H; Moon WS; Chung MJ; Kang MJ; Jang KY
PLoS One; 2013; 8(12):e82870. PubMed ID: 24349382
[TBL] [Abstract][Full Text] [Related]
20. Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis.
Wen YH; Lin HQ; Li H; Zhao Y; Lui VWY; Chen L; Wu XM; Sun W; Wen WP
Cancer Immunol Immunother; 2019 Feb; 68(2):221-232. PubMed ID: 30357458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
